摘要
目的 :评价多沙唑嗪控释片对轻、中度高血压病病人降压有效性及安全性。方法 :采用双盲、双模拟、随机化、平行对照研究方法。 5 8例服多沙唑嗪控释片 4mg ,poqd× 8wk ,5 6例服贝那普利 10mg ,poqd× 8wk。此外 ,对 3 3例开放服多沙唑嗪控释片 4mg ,qd× 8wk。服药前后行 2 4h动态血压监测 (2 4hABPM)。结果 :2组均能有效地降压 ,有效率分别为 81%及 77% (P >0 .0 5 )。多沙唑嗪组不良反应明显少于贝那普利组 (3 %及 2 0 % ) ,P <0 .0 1,无体位性低血压及反射性心动过速。 2 4hABPM示等幅度降日间血压及夜间血压。谷 /峰比值 :SBP为 0 .69,DBP为 0 .5 9。结论 :多沙唑嗪控释片是一种有效安全的长效肾上腺素α1受体阻滞剂。
AIM:To evaluate the efficacy and safety of doxazosin controlled release tablets in patients with mild to moderate essential hypertension. METHODS: A multicenter,double blind,double similarly randomized parallel study was designed. Fifty eight patients received doxazosin (4 mg, po, qd) and fifty six patients received benazepril (10 mg, po, qd) for 8wk. Another 33 patients in open trial received doxazosin with 24 h ambulatory blood pressure monitoring (ABPM) before and after treatment 4 mg, po , qd for 8 wk. RESULTS: The blood pressure significantly decreased after treatment with doxazosin and benazepril and the effective rates were 81% and 77 %, respectively at the end of 8 wk. And the adverse reactions were 3 % and 20 % with no orthostatic hypotension.24h ABPM showed significantly daytime and nighttime blood pressure smoothly reduction and T/P ratio:SBP:0.69, DBP:0.59. CONCLUSION: Doxazosin controlled release tablets is an effective, safe and long acting α 1 receptor blocker and has less adverse reaction than benazepril in treating mild to moderated essential hypertension.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2001年第6期409-412,共4页
Chinese Journal of New Drugs and Clinical Remedies
关键词
多沙唑嗪
贝那普利
高血压
血压测定
血压监测仪
随机对照试验
双盲法
治疗
doxazosin
benazepril
hypertension
blood pressure determination
blood pressure monitors
randomized controlled trials
double blind method
